THERAPEUTIC RESPONSE IN PATIENTS WITH CD30+ LYMPHOMAS TO BIOLOGICAL THERAPY
Abstract
Introduction: Improvements in combined chemotherapy and radiotherapy of the newly diagnosed Hodgkin's lymphoma (HL) resulted in sustained remission rates of approximately 60% to 80%. However, about 5% of the early stages of the disease and 30% to 40% of advanced disease experience relapses after initial chemiotherapy. Standard in the treatment of patients with relapse or refractory HL is salvage therapy followed by autologous stem cell transplantation (ASCT). In approximately 50% patients relapse after ASCT and then effective therapeutic options are limited. Brentuximab vedotin (Adcetris®) is a new antibody-drug conjugate that leads to a high response in the CD30 + lymphomas after ASCT.
Material and methods: Retrospective study included 20 patients, on average aged 53,31 years, that were diagnosed with Hodgkin and Non-Nodgkin lymphomas and treated with Brentuximab vedotin in Clinic for Hematology, Clinical Center of Serbia, in period of 2002 to 2018y. The informations of the patients were gathered and databases have been formed from the history of the disease. Statistical analisis included descriptive statistical methods that were done in SPSS programe.
Results: The objective response rate (CR + PR) was 76,5% with 29.4% complete remissions (CR) and 47.1% partial remissions (PR). Progressive disease was observed in 17,6%. The median duration of the therapeutic response was 9 months.
Conclusion: The application of biological therapy has led to significant progression in the treatment of relapse/refractory Hodgkin's lymphoma, but it is more effective to apply it as a consolidative therapy after ASCT in order to achieve better results of treatment of these patients.
Key words: Hodgkin lymphoma, Brentuximab vedotin, treatment efficacy
References
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–2395.
3. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625–633.
4. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1065–1072.
5. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-33.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10–29.
7. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;97–506.
8. Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531-3.
9. Dürkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68:421–427.
10. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1–14.
11. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848–58.
12. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–1465.
13. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30:2183-9.
14. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22-7.
15. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21
16. Fedele R, Martino M, Recchia AG, et al. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212
17. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-2642.
18. Chen R, Palmer JM, Martin P, et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-2140.
19. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.